4004:TADAWULDallah Healthcare Co. Analysis

Resonac Holdings trades at a very high trailing PE of over 100x and a forward PE near 70x, while its revenue has contracted by roughly 4% YoY and profit margins sit in the low single‑digit range. Technical indicators are mixed: the price sits below the 20‑day SMA but above the 50‑day and 200‑day averages, the RSI is neutral around 52, and the MACD histogram is negative, suggesting short‑term downside pressure.
The balance sheet is heavily leveraged with a debt‑to‑equity ratio exceeding 130, and cash flow generation is currently flat, raising concerns about the sustainability of the modest 0.38% dividend. Nonetheless, the stock enjoys a bullish trend classification, low volatility relative to its 30‑day swing (≈73% annualized) and a solid market cap, which mitigates liquidity risk. Investors should weigh the high valuation and financial strain against the positive analyst consensus and the company’s diversified chemical portfolio.